A
Alberto Gobbi
Researcher at European Institute of Oncology
Publications - 161
Citations - 7986
Alberto Gobbi is an academic researcher from European Institute of Oncology. The author has contributed to research in topics: Anterior cruciate ligament reconstruction & Cartilage. The author has an hindex of 41, co-authored 148 publications receiving 7364 citations.
Papers
More filters
Journal Article
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.
Francesco Bertolini,Saki Paul,Patrizia Mancuso,Silvia Monestiroli,Alberto Gobbi,Yuval Shaked,Robert S. Kerbel +6 more
TL;DR: The findings suggest that metronomic low-dose chemotherapy regimens are particularly promising for avoiding CEP mobilization and, hence, to potentially reduce vasculogenesis-dependent mechanisms of tumor growth.
Journal ArticleDOI
Articular cartilage engineering with Hyalograft C: 3-year clinical results.
Maurilio Marcacci,Massimo Berruto,Domenico Brocchetta,A. Delcogliano,Diego Ghinelli,Alberto Gobbi,E. Kon,Luigi Adriano Pederzini,D Rosa,Gian Luigi Sacchetti,Giacomo Stefani,Stefano Zanasi +11 more
TL;DR: Positive clinical results obtained indicate that Hyalograft® C is a safe and effective therapeutic option for the treatment of articular cartilage lesions and a very limited complication rate was recorded in this study.
Journal ArticleDOI
Arthroscopic Second-Generation Autologous Chondrocyte Implantation Compared With Microfracture for Chondral Lesions of the Knee Prospective Nonrandomized Study at 5 Years
Elizaveta Kon,Alberto Gobbi,Giuseppe Filardo,Marco Delcogliano,Stefano Zaffagnini,Maurilio Marcacci +5 more
TL;DR: Both methods have shown satisfactory clinical outcome at medium-term follow-up and better clinical results and sport activity resumption were noted in the group treated with second-generation autologous chondrocyte transplantation.
Journal ArticleDOI
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity
Davide Danovi,Erik Meulmeester,Diego Pasini,Domenico Migliorini,Maria Capra,Ruth Frenk,Petra de Graaf,Sarah Francoz,Patrizia Gasparini,Alberto Gobbi,Kristian Helin,Pier Giuseppe Pelicci,Aart G. Jochemsen,Jean-Christophe Marine +13 more
TL;DR: It is shown that retrovirus-mediated Mdmx overexpression allows primary mouse embryonic fibroblast immortalization and leads to neoplastic transformation in combination with HRasV12, and this results make Hdmx a new putative drug target for cancer therapy.
Journal ArticleDOI
Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation.
TL;DR: The results demonstrate no difference between chondroplasty, microfracture, and OAT with regard to AHS and SANE ratings in patients with OLT, however, NPI at 24 hours postoperatively was significantly lower in patients who had chondraplasty and microFracture.